A FRT-flanked p53 mouse to generate primary tumors with Flp recombinase
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: The site-specific recombinases Cre and Flp can mutate genes in a spatially and temporally restricted manner in mice. Conditional recombination of the tumor suppressor p53 using the Cre-loxP system has led to the development of multiple genetically engineered mouse models of human cancer. However, initiation of tumors with Cre recombinase limits the utilization of Cre to genetically modify other genes in stromal cells. To overcome this limitation, we inserted FRT sites flanking exons 2 through 6 of the endogenous p53 gene in mice to generate a p53FRT allele that can be deleted by Flp recombinase. We show that FlpO-mediated deletion of p53 in mouse embryonic fibroblasts impairs the p53-dependent response to genotoxic stress in vitro. In addition, using FSF-KrasG12D/+; p53FRT/FRT mice, we demonstrate an adenovirus expressing FlpO recombinase can initiate primary lung cancers and sarcomas in mice. p53FRT mice will enable dual recombinase technology to study cancer biology because Cre is available to modify genes specifically in stromal cells to investigate their role in tumor development, progression, and response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
p53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459 · cited 2×
“Interestingly, a mouse with deletion of the first six exons of p53 was previously reported to express a truncated RNA capable of coding for the C-terminus of the p53 protein that can be detected only after in vitro translation (Tyner et al., 2002).”
BackgroundResultWhen mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 1×
“The transformation related protein p53 gene, Trp53, is the most frequently mutated gene in human cancer, altered in approximately 50% of human malignancies (Brosh and Rotter, 2009).”
BackgroundMarino, S., Vooijs, M., van der Gulden, H., Jonkers, J., & Berns, A. (2000) · Genes & Development · doi:10.1101/gad.14.8.994 · Cited by 920
Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
The p53 family in differentiation and tumorigenesis
Stiewe, T. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2072 · Cited by 306 · cited 1×
“The p53 response varies across cell and tissue types, and involves a spectrum from transient cell cycle arrest to senescence and apoptosis (Stiewe, 2007).”
BackgroundMartínez-Cruz, A. B., Santos, M., Lara, M. F., Segrelles, C., Ruiz, S., Moral, M., Lorz, C., García-Escudero, R., & Paramio, J. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3049 · Cited by 65
Cited by
Dietary methionine influences therapy in mouse cancer models and alters human metabolism
Gao, X., Sanderson, S. M., Dai, Z., Reid, M. A., Cooper, D. E., Lu, M., Richie, J. P., Ciccarella, A., Calcagnotto, A., Mikhael, P. G., et al. (2019) · Nature · doi:10.1038/s41586-019-1437-3 · Cited by 636
Self-citationChen, Y., Kim, J., Yang, S., Wang, H., Wu, C.-J., Sugimoto, H., LeBleu, V. S., & Kalluri, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.007 · Cited by 566
“EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice—FSF-KrasG12D/+ (Schonhuber et al., 2014), Pdx1-Flp (Schonhuber et al., 2014), Trp53frt/+ (Lee et al., 2012), αSMA-Cre (LeBleu et al., 2013), and Fsp1-Cre (Bhowmick et al., 2004; Xue et al., 2003) mouse strains were previously documented.”
Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
Mueller, S., Engleitner, T., Maresch, R., Zukowska, M., Lange, S., Kaltenbacher, T., Konukiewitz, B., Öllinger, R., Zwiebel, M., Strong, A., et al. (2018) · Nature · doi:10.1038/nature25459 · Cited by 431
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370
A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma
Tammela, T., Sanchez-Rivera, F. J., Cetinbas, N. M., Wu, K., Joshi, N. S., Helenius, K., Park, Y., Azimi, R., Kerper, N. R., Wesselhoeft, R. A., et al. (2017) · Nature · doi:10.1038/nature22334 · Cited by 336
Metadata
- Authors
- Lee, C.-L., Moding, E. J., Huang, X., Li, Y., Woodlief, L. Z., Rodrigues, R. C., Ma, Y., & Kirsch, D. G.
- Venue
- Disease Models & Mechanisms
- Publisher
- The Company of Biologists
- Published
- 2011-01-01
- Volume
- 5
- Issue
- 3
- Pages
- 397-402
- ISSN
- 1754-8403 (ISSN-L)
- 1754-8411
- OpenAlex
- W2106804121
- Cited by
- 69
- References
- 7
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.